ZCure LLC
To enhance the anti-cancer effects of currently existing medications and biologics with nanotechnology (US Patent Approved)
The mission of our company is to develop nanoformulations of currently available FDA-approved medications or biologics to better serve as anti-cancer therapeutics and shorten the process of cancer drug development. Synthetic and naturally existing nanoparticles such as exosomes are both used for enhanced tumor-specific drug delivery. We particularly focus on nanoformulations of drugs that can penetrate blood-brain barrier for treating brain tumors.
Staff
Yvette Yuanyuan Jia, MS, CEO/CFO
Chi Zhang, MD, PhD, CSO
Svetlana Romanova, PhD, Senior director for drug manufacturing, Co-inventor of our product
Scientific Advisory board
Dr. Charles Enke, UNMC
Dr. Chi Lin, UNMC
Dr. David Oupicky, UNMC
Dr. Oren Becher, Pediatric/Mount Sinai, New York
Dr. Tony Wang, Radiation Oncology/Columbia U Med Center, New York
Points of Contact
Yuanyuan Jia, CEO/CFO
zyinewzhang@gmail.com
ZCure LLC
To enhance the anti-cancer effects of currently existing medications and biologics with nanotechnology (US Patent Approved)
The mission of our company is to develop nanoformulations of currently available FDA-approved medications or biologics to better serve as anti-cancer therapeutics and shorten the process of cancer drug development. Synthetic and naturally existing nanoparticles such as exosomes are both used for enhanced tumor-specific drug delivery. We particularly focus on nanoformulations of drugs that can penetrate blood-brain barrier for treating brain tumors.
Staff
Yvette Yuanyuan Jia, MS, CEO/CFO
Chi Zhang, MD, PhD, CSO
Svetlana Romanova, PhD, Senior director for drug manufacturing, Co-inventor of our product
Scientific Advisory board
Dr. Charles Enke, UNMC
Dr. Chi Lin, UNMC
Dr. David Oupicky, UNMC
Dr. Oren Becher, Pediatric/Mount Sinai, New York
Dr. Tony Wang, Radiation Oncology/Columbia U Med Center, New York
Points of Contact
Yuanyuan Jia, CEO/CFO
zyinewzhang@gmail.com